Pulmatrix (NASDAQ:PULM) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Pulmatrix (NASDAQ:PULMFree Report) in a report published on Monday. The brokerage issued a hold rating on the biotechnology company’s stock.

Pulmatrix Trading Up 8.5 %

Shares of NASDAQ PULM opened at $6.10 on Monday. The firm has a fifty day simple moving average of $2.57 and a two-hundred day simple moving average of $2.21. Pulmatrix has a 12 month low of $1.55 and a 12 month high of $8.44. The firm has a market capitalization of $22.27 million, a PE ratio of -2.31 and a beta of 0.99.

About Pulmatrix

(Get Free Report)

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.

Recommended Stories

Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.